MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Prognosis for acute myeloid leukemia (AML) remains unfavorable for many, often due to disease recurrence after remission.
• Measurable residual disease (MRD) detection post-treatment is a key prognostic factor, predicting relapse and enabling early intervention.
• Standard MRD detection methods include multiparameter flow cytometry and quantitative PCR, with next-generation sequencing offering broader applicability.

Purpose of the Study:

• To review and discuss recent data on the interpretation and role of MRD in AML patients treated with venetoclax-based combinations.
• To address the limited experience with MRD monitoring in patients receiving low-intensity regimens, including novel agents like venetoclax.
• To consolidate evidence regarding the impact of MRD negativity on outcomes in the context of venetoclax-based therapies.

Main Methods:

• Review of recent scientific literature and clinical data on MRD detection and interpretation in AML.
• Analysis of studies focusing on venetoclax-based treatment regimens in AML patients, particularly elderly or unfit individuals.
• Examination of established MRD threshold levels and their correlation with outcomes in intensive treatment settings.

Main Results:

• Venetoclax combined with hypomethylating agents or low-dose cytarabine shows good tolerability and high response rates in AML patients.
• While MRD negativity correlates with improved outcomes after intensive chemotherapy, supporting data for venetoclax-based regimens is still consolidating.
• Limited data currently exists on MRD monitoring and interpretation specifically for patients on low-intensity venetoclax-based treatments.

Conclusions:

• Further research is needed to establish definitive MRD monitoring strategies and interpretative thresholds for venetoclax-based AML treatments.
• Understanding MRD dynamics in patients receiving novel, low-intensity therapies is critical for optimizing treatment and improving patient outcomes.
• The role of MRD in predicting relapse and guiding therapeutic decisions in the era of targeted AML therapies requires continued investigation.